Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00428090
First received: January 25, 2007
Last updated: February 13, 2014
Last verified: February 2014
  Purpose

Rosiglitazone (RSG) has been tested and is approved as a treatment for type II diabetes mellitus, a disease that occurs when the body ineffectively uses glucose. RSG XR, the investigational drug, is an extended-release form of RSG. This study tests whether RSG XR safely provides benefit to people with mild to moderate Alzheimer's disease (AD). RSG XR is a new approach to AD therapy and this study tests whether one's genes alter the effectiveness of RSG XR. Glucose is used by cells to make energy that they need to live. Changes in the ability of cells to use of glucose can lead to diseases like diabetes. Glucose levels may be lower in the brains of AD patients, and their brain cells may also use glucose less well than in unaffected people. The proper function of brain cells may be critical to memory and thought. If brain cells use glucose poorly, this might impact AD. Drugs that help brain cells properly use glucose may help a person maintain normal memory and thinking. Data suggesting that RSG may help AD patients was first seen in a small study at the Univ. of Washington and then from a larger international GSK study. In the first study, those receiving RSG once daily for 6 months scored better on 3 tests of memory and thought than those who did not receive RSG. In the GSK study, those that benefited most from therapy with RSG XR had a specific genetic pattern. They lacked the gene that caused them to produce apolipoprotein E e4 (APOE e4). Subjects who have the APOE e4 gene may have two copies, one from each parent, or they may have only one APOE e4 gene meaning that they inherited either the APOE e2 or APOE e3 version of the gene from one parent. Subjects with one copy of the APOE e4 gene remained fairly stable while those with two copies of APOE e4 continued to worsen during the 6-month treatment. This study will directly test the effect of RSG XR on people who either have or lack the APOE e4 gene.


Condition Intervention Phase
Alzheimer's Disease
Drug: Rosiglitazone
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A 24-week, Double-blind, Double-dummy, Randomized, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets), Donepezil, and Placebo as Monotherapy on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease. (REFLECT-1)

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Change from baseline in ADAS-Cog total score and CIBIC+ score at Week 24, as a function of APOE e4 status.

Secondary Outcome Measures:
  • Visits Week 4 to 24:changes in behavior, activities of daily living, healthcare resource utilization, subject/ caregiver quality of life, pharmacokinetics, exploratory pharmacogenetics, proteomics/transcriptomics. [ Time Frame: 24 Weeks ]
  • The following endpoints will be analyzed according to a prioritized hierarchy to preserve the type I error rate :
  • Change from baseline in ADAS-Cog total score for observed cases at Weeks 8, 16 and 24.
  • Change from baseline in CIBIC+ score for observed cases at Weeks 8, 16 and 24.
  • Change from baseline in Neuropsychiatric Inventory (NPI; [Cummings, 1994]) total score.
  • Change from baseline in Disability Assessment for Dementia scale (DAD; [Gelinas, 1999]) total score.
  • Combined analysis of Items 1 and 7 of ADAS-Cog to yield Short Term Memory Assessment
  • Change from baseline in European Quality of Life -5 Dimensions Proxy (EQ-5D Proxy) scale [The EuroQol Group, 1990] total score.
  • Domains of the Resource Utilization in Dementia scale (RUD; [Wimo, 1998]).
  • Change from baseline in Alzheimer's Carer's Quality of Life Instrument (ACQLI, [Doward, 1997]) score.
  • Change from baseline in Mini Mental State Examination (MMSE) [Folstein, 1975] total score.
  • Change from baseline in HbA1c at Week 24.

Enrollment: 862
Study Start Date: February 2007
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Rosiglitazone
XR (extended release) oral tablets
Drug: Rosiglitazone
XR (extended release) oral tablets
Placebo
Placebo (Double-Dummy to Match)
Drug: Rosiglitazone
XR (extended release) oral tablets

Detailed Description:

A 24-week, double-blind, double-dummy, randomized, parallel-group study to investigate the effects of rosiglitazone (extended release tablets), donepezil, and placebo as monotherapy on cognition and overall clinical response in APOE e4-stratified subjects with mild to moderate Alzheimer's disease. (REFLECT-1)

  Eligibility

Ages Eligible for Study:   50 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • Clinical diagnosis of probable Alzheimer's Disease (AD).
  • MMSE score 10 to 23
  • Has not taken an approved AD therapy in last 30 days.
  • No previous hypersensitivity/intolerance to AChEIs
  • Have a regular caregiver.

Exclusion criteria:

  • Diagnosis of vascular dementia.
  • Type I or secondary diabetes mellitus.
  • Type II diabetes mellitus treated with insulin, sulfonylurea or glipizide.
  • History or evidence of congestive heart failure, clinically significant peripheral edema or anemia.
  • History of significant psychiatric illness, major depressive disorder or current depression needing initiation of treatment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00428090

  Hide Study Locations
Locations
United States, Arizona
GSK Investigational Site
Phoenix, Arizona, United States, 85004
United States, California
GSK Investigational Site
Los Angeles, California, United States, 90036
GSK Investigational Site
Newport Beach, California, United States, 92660
GSK Investigational Site
Palo Alto, California, United States, 94305
GSK Investigational Site
Reseda, California, United States, 91355
GSK Investigational Site
San Diego, California, United States, 92120
GSK Investigational Site
San Francisco, California, United States, 94109
United States, Colorado
GSK Investigational Site
Denver, Colorado, United States, 80218
United States, Connecticut
GSK Investigational Site
Fairfield, Connecticut, United States, 06824
GSK Investigational Site
Norwalk, Connecticut, United States, 06851
United States, Florida
GSK Investigational Site
Deerfield Beach, Florida, United States, 33064
GSK Investigational Site
Delray Beach, Florida, United States, 33445
GSK Investigational Site
Destin, Florida, United States, 32541
GSK Investigational Site
Hialeah, Florida, United States, 33016
GSK Investigational Site
Melbourne, Florida, United States, 32901
GSK Investigational Site
Plantation, Florida, United States, 33317
GSK Investigational Site
Sunrise, Florida, United States, 33351
GSK Investigational Site
Tampa, Florida, United States, 33647
United States, Georgia
GSK Investigational Site
Atlanta, Georgia, United States, 30033
United States, Minnesota
GSK Investigational Site
St. Paul, Minnesota, United States, 55101
United States, Nevada
GSK Investigational Site
Las Vegas, Nevada, United States, 89146
United States, New Jersey
GSK Investigational Site
Kenilworth, New Jersey, United States, 07033
GSK Investigational Site
Toms River, New Jersey, United States, 08755
United States, New York
GSK Investigational Site
Albany, New York, United States, 12208
GSK Investigational Site
Syracuse, New York, United States, 13210
United States, Ohio
GSK Investigational Site
Centerville, Ohio, United States, 45459
GSK Investigational Site
Cleveland, Ohio, United States, 44120
GSK Investigational Site
Cleveland, Ohio, United States, 44195
GSK Investigational Site
Toledo, Ohio, United States, 43623
United States, Oklahoma
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73112
GSK Investigational Site
Oklahoma City, Oklahoma, United States, 73118
GSK Investigational Site
Tulsa, Oklahoma, United States, 74104
United States, Pennsylvania
GSK Investigational Site
Jenkintown, Pennsylvania, United States, 19046
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19102
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19104
United States, Tennessee
GSK Investigational Site
Memphis, Tennessee, United States, 35105
GSK Investigational Site
Nashville, Tennessee, United States, 37212
United States, Texas
GSK Investigational Site
DeSoto, Texas, United States, 75115
GSK Investigational Site
San Antonio, Texas, United States, 78229
GSK Investigational Site
San Antonio, Texas, United States, 78229-3900
United States, Wisconsin
GSK Investigational Site
Middleton, Wisconsin, United States, 53562-2215
Austria
GSK Investigational Site
Graz-Eggenberg, Austria, A-8020
GSK Investigational Site
Hall in Tirol, Austria, A-6060
GSK Investigational Site
Linz, Austria, A-4020
GSK Investigational Site
Linz, Austria, 4020
GSK Investigational Site
Vienna, Austria, A-1130
GSK Investigational Site
Vienna, Austria, A-1090
GSK Investigational Site
Vienna, Austria, 1030
Bulgaria
GSK Investigational Site
Plovdiv, Bulgaria, 4000
GSK Investigational Site
Sofia, Bulgaria, 1113
GSK Investigational Site
Sofia, Bulgaria, 1527
GSK Investigational Site
Sofia, Bulgaria, 1431
Chile
GSK Investigational Site
Providencia / Santiago, Región Metro De Santiago, Chile, 7500710
GSK Investigational Site
Puente Alto - Santiago, Región Metro De Santiago, Chile, 8207257
GSK Investigational Site
Santiago, Región Metro De Santiago, Chile, 7560356
GSK Investigational Site
Viña del Mar, Valparaíso, Chile, 252-0997
China, Guangdong
GSK Investigational Site
Guangzhou, Guangdong, China, 510370
China
GSK Investigational Site
Beijing, China, 100730
GSK Investigational Site
Beijing, China, 100083
GSK Investigational Site
Shanghai, China, 200025
GSK Investigational Site
Shanghai, China, 200030
GSK Investigational Site
Shanghai, China, 200040
GSK Investigational Site
Tianjin, China, 300052
Croatia
GSK Investigational Site
Dubrovnik, Croatia, 20000
GSK Investigational Site
Zagreb, Croatia, 10000
Estonia
GSK Investigational Site
Tallinn, Estonia, 10138
GSK Investigational Site
Tallinn, Estonia, 10617
GSK Investigational Site
Tallinn, Estonia, 10614
GSK Investigational Site
Tartu, Estonia, 51014
Germany
GSK Investigational Site
Ellwangen, Baden-Wuerttemberg, Germany, 73479
GSK Investigational Site
Tuebingen, Baden-Wuerttemberg, Germany, 72076
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89075
GSK Investigational Site
Ulm, Baden-Wuerttemberg, Germany, 89073
GSK Investigational Site
Guenzburg, Bayern, Germany, 89312
GSK Investigational Site
Muenchen, Bayern, Germany, 81675
GSK Investigational Site
Muenchen, Bayern, Germany, 80331
GSK Investigational Site
Nuernberg, Bayern, Germany, 90402
GSK Investigational Site
Unterhaching, Bayern, Germany, 82008
GSK Investigational Site
Bad Homburg, Hessen, Germany, 61348
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19053
GSK Investigational Site
Schwerin, Mecklenburg-Vorpommern, Germany, 19055
GSK Investigational Site
Achim, Niedersachsen, Germany, 28832
GSK Investigational Site
Hannover, Niedersachsen, Germany, 30559
GSK Investigational Site
Baesweiler, Nordrhein-Westfalen, Germany, 52499
GSK Investigational Site
Bielefeld, Nordrhein-Westfalen, Germany, 33647
GSK Investigational Site
Bochum, Nordrhein-Westfalen, Germany, 44892
GSK Investigational Site
Duisburg, Nordrhein-Westfalen, Germany, 47051
GSK Investigational Site
Juelich, Nordrhein-Westfalen, Germany, 52428
GSK Investigational Site
Koeln, Nordrhein-Westfalen, Germany, 50767
GSK Investigational Site
Halle, Sachsen-Anhalt, Germany, 06122
GSK Investigational Site
Chemnitz, Sachsen, Germany, 09111
GSK Investigational Site
Dresden, Sachsen, Germany, 01097
GSK Investigational Site
Dresden, Sachsen, Germany, 01307
GSK Investigational Site
Leipzig, Sachsen, Germany, 04103
GSK Investigational Site
Itzehoe, Schleswig-Holstein, Germany, 25524
GSK Investigational Site
Gera, Thueringen, Germany, 07551
GSK Investigational Site
Berlin, Germany, 12167
GSK Investigational Site
Berlin, Germany, 14163
GSK Investigational Site
Berlin, Germany, 12163
GSK Investigational Site
Berlin, Germany, 13125
GSK Investigational Site
Berlin, Germany, 13507
GSK Investigational Site
Hamburg, Germany, 22083
GSK Investigational Site
Hamburg, Germany, 20249
GSK Investigational Site
Hamburg, Germany, 22143
Greece
GSK Investigational Site
Athens, Greece, 115 21
GSK Investigational Site
Melissia, Greece, 151 27
GSK Investigational Site
Thessaloniki, Greece, 57010
Hungary
GSK Investigational Site
Budapest, Hungary, 1106
GSK Investigational Site
Gyula, Hungary, 5700
GSK Investigational Site
Kaposvár, Hungary, 7400
GSK Investigational Site
Pécs, Hungary, 7623
GSK Investigational Site
Szeged, Hungary, 6725
India
GSK Investigational Site
Bangalore, India, 560034
GSK Investigational Site
Nagpur, India, 440010
GSK Investigational Site
Tirupati, India, 517507
Korea, Republic of
GSK Investigational Site
Seongnam-si,, Korea, Republic of, 463-707
GSK Investigational Site
Seoul, Korea, Republic of, 143-729
Mexico
GSK Investigational Site
Saltillo, Coahuila, Mexico, 25000
GSK Investigational Site
Monterrey, Nuevo León, Mexico, 64660
GSK Investigational Site
Mexico, Mexico, 14000
New Zealand
GSK Investigational Site
Auckland, New Zealand, 0622
Pakistan
GSK Investigational Site
Karachi, Pakistan, 74800
GSK Investigational Site
Lahore, Pakistan, 54590
GSK Investigational Site
Lahore, Pakistan, 54000
Peru
GSK Investigational Site
Lima, Peru, Lima 13
Philippines
GSK Investigational Site
Pasig City, Philippines, 1600
GSK Investigational Site
Quezon City, Philippines, 1102
Puerto Rico
GSK Investigational Site
Cabo Rojo, Puerto Rico, 623
GSK Investigational Site
San Juan, Puerto Rico, 90660
GSK Investigational Site
San Juan, Puerto Rico, 00918
Russian Federation
GSK Investigational Site
Moscow, Russian Federation, 115522
GSK Investigational Site
Moscow, Russian Federation, 115552
GSK Investigational Site
Moscow, Russian Federation, 117049
GSK Investigational Site
St. Petersburg, Russian Federation, 197022
GSK Investigational Site
St.-Petersburg, Russian Federation, 198103
United Kingdom
GSK Investigational Site
Bradford, United Kingdom, BD3 0DQ
GSK Investigational Site
Derriford, Plymouth, United Kingdom, PL6 8BX
GSK Investigational Site
West of Scotland Science Park, Glasgow, United Kingdom, G20 0XA
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided by GlaxoSmithKline

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00428090     History of Changes
Other Study ID Numbers: 105640
Study First Received: January 25, 2007
Last Updated: February 13, 2014
Health Authority: United States: Food and Drug Administration
United Kingdom: Medicines and Healthcare Products Regulatory Agency

Keywords provided by GlaxoSmithKline:
apolipoprotein E
monotherapy
cognition
mild
rosiglitazone
Alzheimer's disease
moderate

Additional relevant MeSH terms:
Alzheimer Disease
Rosiglitazone
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on July 20, 2014